Clinical Trial Update: A Study of TY-1091 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update for TY-1091 in patients with RET-altered solid tumors, including RET-altered non-small cell lung cancer and thyroid cancers; s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Cancer
• Neoplasms
• Ret-altered Non-small Cell Lung Cancer
• Ret-altered Papillary Thyroid Cancer

Drugs mentioned

• TY-1091 (TY-1091)

Snippet

Sponsor: TYK Medicines, Inc | Conditions: RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1, Phase 2 | Status: UNKNOWN